Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, By Region, And Segment Forecasts, 2025 - 2030

Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report By Disease (Cancer, Infectious Diseases), By Grade (R&D, GMP), By Application, By Development Phase, By Region, And Segment Forecasts, 2025 - 2030


Trypsin Market Growth & Trends

The global trypsin market size is estimated to reach USD 131.5 billion by 2030, registering a CAGR of 5.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing adoption of trypsin across various industries, such as pharmaceuticals, food science research, detergents, and leather-bating, is likely to drive the market growth. Where as various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis, along with increasing focus on drug discovery and development is expected to further propel the market growth.

Trypsin is widely being used in R&D in pharmaceutical, food, and environmental industries, owing to its special digestive functions of hydrolyzing proteins. It acts as a raw material for internal medicine in endocrine diseases and clinical surgery. The use of enzyme catalysts has been scaled up for commercial processes in the pharmaceutical, beverages, and food industries. These enzymes help in waste reduction, which makes them highly efficient to be used in food, pharmaceuticals, and feed industries. Moreover, the best source of trypsin, TRYPSIN VI, has found nutraceutical use as an anti-inflammatory treatment and a digestive supplement for veterinary & human applications.

Various research studies are being conducted to evaluate its potential in diagnosing a wide range of disorders, such as cancer, acute pancreatitis, malabsorption, and cystic fibrosis. Increase in R&D expenditure, the rising drug launches, and FDA approvals.

Trypsin Market Report Highlights
  • Based on source, the bovine segment led the market with the largest revenue share of 59.71% in 2024, owing to prominent application in field of clinical diagnostics, research, food and beverage industry and meat tenderization
  • Based on source, the porcine segment is expected to grow at the significant CAGR over the forecast period
  • Based on application, the biotechnology and pharmaceutical industry segment held the market with the largest revenue share of 56.40% in 2024, and is further anticipated to witness the fastest CAGR over the forecast period. The increasing focus on drug discovery and development is further propelling growth
  • North America dominated the market with the largest revenue share of 40.49% in 2024, owing to factors such as increasing the prevalence of various cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
  • In Dec 2023, Creative Enzymes, a global pioneer in professional enzyme related products and services unveiled its combination product offerings for proteolytic enzymes such as Trypsin-Chymotrypsin, with this company aims at optimizing the speed and efficiency of the digestive process opening new possibilities for medical and pharmaceutical enhancements.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Grade
1.2.2. Development Phase
1.2.3. Application
1.2.4. Disease
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.9.1. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Increasing number of patients opting for gene therapy
3.3.2. Robust pipeline for gene therapies
3.3.3. Highly competitive market and various strategies undertaken by market players
3.3.4. Increasing demand for plasmid DNA in various medical therapies
3.4. Market Restraint Analysis
3.4.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy
3.5. Business Environment Analysis
3.5.1. PESTEL Analysis
3.5.2. Porter’s Five Forces Analysis
3.5.3. COVID-19 Impact Analysis
Chapter 4. Grade Business Analysis
4.1. Segment Dashboard
4.2. Global Plasmid DNA Manufacturing Market Movement Analysis
4.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Grade, 2018 to 2030 (USD Million)
4.4. R&D Grade
4.4.1. R&D Grade Market, 2018 - 2030 (USD Million)
4.4.2. Viral Vector Development
4.4.2.1. Viral Vector Development Market, 2018 - 2030 (USD Million)
4.4.2.2. AAV
4.4.2.2.1. AAV Market, 2018 - 2030 (USD Million)
4.4.2.3. Lentivirus
4.4.2.3.1. Lentivirus Market, 2018 - 2030 (USD Million)
4.4.2.4. Adenovirus
4.4.2.4.1. Adenovirus Market, 2018 - 2030 (USD Million)
4.4.2.5. Retrovirus
4.4.2.5.1. Retrovirus Market, 2018 - 2030 (USD Million)
4.4.2.6. Others
4.4.2.6.1. Others Market, 2018 - 2030 (USD Million)
4.4.3. mRNA Development
4.4.3.1. mRNA Development Market, 2018 - 2030 (USD Million)
4.4.4. Antibody Development
4.4.4.1. Antibody Development Market, 2018 - 2030 (USD Million)
4.4.5. DNA Vaccine Development
4.4.5.1. DNA Vaccine Development Market, 2018 - 2030 (USD Million)
4.4.6. Others
4.4.6.1. Others Market, 2018 - 2030 (USD Million)
4.5. GMP Grade
4.5.1. GMP Grade Market, 2018 - 2030 (USD Million)
Chapter 5. Development Phase Business Analysis
5.1. Segment Dashboard
5.2. Global Plasmid DNA Manufacturing Market Movement Analysis
5.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Development Phase, 2018 to 2030 (USD Million)
5.4. Pre-Clinical Therapeutics
5.4.1. Pre-Clinical Therapeutics Market, 2018 - 2030 (USD Million)
5.5. Clinical Therapeutics
5.5.1. Clinical Therapeutics Market, 2018 - 2030 (USD Million)
5.6. Marketed Therapeutics
5.6.1. Marketed Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 6. Application Business Analysis
6.1. Segment Dashboard
6.2. Global Plasmid DNA Manufacturing Market Movement Analysis
6.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. DNA Vaccines
6.4.1. DNA Vaccines Market, 2018 - 2030 (USD Million)
6.5. Cell & Gene Therapy
6.5.1. Cell & Gene Therapy Market, 2018 - 2030 (USD Million)
6.6. Immunotherapy
6.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. Disease Business Analysis
7.1. Segment Dashboard
7.2. Global Plasmid DNA Manufacturing Market Movement Analysis
7.3. Global Plasmid DNA Manufacturing Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
7.4. Infectious Disease
7.4.1. Infectious Disease Market, 2018 - 2030 (USD Million)
7.5. Cancer
7.5.1. Cancer Market, 2018 - 2030 (USD Million)
7.6. Genetic Disorder
7.6.1. Genetic Disorder Market, 2018 - 2030 (USD Million)
7.7. Others
7.7.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. Regional Estimates & Trend Analysis by Grade, Development Phase, Disease, & Application
8.1. Regional Market Dashboard
8.2. Global Plasmid DNA Manufacturing Market Share By Region, 2024 & 2030
8.3. North America
8.3.1. North America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.3.2. U.S.
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. Target Disease Prevalence
8.3.2.5. U.S. Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Target Disease Prevalence
8.3.3.5. Canada Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Target Disease Prevalence
8.3.4.5. Mexico Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4. Europe
8.4.1. Europe Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. Target Disease Prevalence
8.4.2.5. Germany Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.3. UK
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Target Disease Prevalence
8.4.3.5. UK Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. Target Disease Prevalence
8.4.4.5. France Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Target Disease Prevalence
8.4.5.5. Italy Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Target Disease Prevalence
8.4.6.5. Spain Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Target Disease Prevalence
8.4.7.5. Denmark Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Target Disease Prevalence
8.4.8.5. Sweden Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Target Disease Prevalence
8.4.9.5. Norway Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Target Disease Prevalence
8.5.2.5. Japan Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Target Disease Prevalence
8.5.3.5. China Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Target Disease Prevalence
8.5.4.5. India Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Target Disease Prevalence
8.5.5.5. South Korea Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.6. Australia
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Target Disease Prevalence
8.5.6.5. Australia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.5.7. Thailand
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Target Disease Prevalence
8.5.7.5. Thailand Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.6. Latin America
8.6.1. Latin America Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Target Disease Prevalence
8.6.2.5. Brazil Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Target Disease Prevalence
8.6.3.5. Argentina Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.7. MEA
8.7.1. MEA Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Target Disease Prevalence
8.7.2.5. South Africa Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.7.3. Saudi Arabia
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Target Disease Prevalence
8.7.3.5. Saudi Arabia Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.7.4. UAE
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. Target Disease Prevalence
8.7.4.5. UAE Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Target Disease Prevalence
8.7.5.5. Kuwait Plasmid DNA Manufacturing Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Company Market Position Analysis, 2024
9.3. Participant’s Overview
9.3.1. Charles River Laboratories
9.3.1.1. Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Danaher
9.3.2.1. Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. VGXI, Inc.
9.3.3.1. Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Kaneka Corp.
9.3.4.1. Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Lonza
9.3.5.1. Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Nature Technology
9.3.6.1. Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Cell and Gene Therapy Catapult
9.3.7.1. Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Eurofins Genomics
9.3.8.1. Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Luminous BioSciences, LLC
9.3.9.1. Overview
9.3.9.2. Financial Performance
9.3.9.3. Product Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Akron Biotech
9.3.10.1. Overview
9.3.10.2. Financial Performance
9.3.10.3. Product Benchmarking
9.3.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings